Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: Integration and evolution of genetic diagnosis

Hopkins, 2011, Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia, J Clin Lipidol, 5, S9, 10.1016/j.jacl.2011.03.452

Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society, Eur heart J, 35, 2146, 10.1093/eurheartj/ehu274

Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur heart J, 34, 3478, 10.1093/eurheartj/eht273

Futema, 2015, Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries, Clin Chem, 61, 231, 10.1373/clinchem.2014.231365

Hobbs, 1992, Molecular genetics of the LDL receptor gene in familial hypercholesterolemia, Hum Mutat, 1, 445, 10.1002/humu.1380010602

Usifo, 2012, Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment, Ann Hum Genet, 76, 387, 10.1111/j.1469-1809.2012.00724.x

Bertolini, 2013, Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy, Atherosclerosis, 227, 342, 10.1016/j.atherosclerosis.2013.01.007

Garcia-Garcia, 2011, Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family, Atherosclerosis, 218, 423, 10.1016/j.atherosclerosis.2011.07.106

Silva, 2012, In vitro functional characterization of missense mutations in the LDLR gene, Atherosclerosis, 225, 128, 10.1016/j.atherosclerosis.2012.08.017

Etxebarria, 2012, Functional characterization of splicing and ligand-binding domain variants in the LDL receptor, Hum Mutat, 33, 232, 10.1002/humu.21630

Etxebarria, 2014, Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats, Atherosclerosis, 238, 304, 10.1016/j.atherosclerosis.2014.12.026

Calandra, 2011, Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk, J lipid Res, 52, 1885, 10.1194/jlr.R017855

Raponi, 2010, Alternative splicing: good and bad effects of translationally silent substitutions, FEBS J, 277, 836, 10.1111/j.1742-4658.2009.07519.x

Ho, 2015, LDLR gene synonymous mutation c.1813C > T results in mRNA splicing variation in a kindred with familial hypercholesterolaemia, Ann Clin Biochem, 10.1177/0004563215572702

Holla, 2009, Effects of intronic mutations in the LDLR gene on pre-mRNA splicing: comparison of wet-lab and bioinformatics analyses, Mol Genet Metab, 96, 245, 10.1016/j.ymgme.2008.12.014

Baralle, 2005, Splicing in action: assessing disease causing sequence changes, J Med Genet, 42, 737, 10.1136/jmg.2004.029538

Tveten, 2006, Analysis of alternatively spliced isoforms of human LDL receptor mRNA, Clin Chim Acta Int J Clin Chem, 373, 151, 10.1016/j.cca.2006.05.031

Medina, 2011, Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PloS one, 6, e19420, 10.1371/journal.pone.0019420

Chan, 1997, Surface expression of low density lipoprotein receptor in EBV-transformed lymphocytes: characterization and use for studying familial hypercholesterolemia, Atherosclerosis, 131, 149, 10.1016/S0021-9150(97)06086-3

Romano, 2010, Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy, Atherosclerosis, 210, 493, 10.1016/j.atherosclerosis.2009.11.051

Romano, 2011, An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations, J Lipid Res, 52, 2095, 10.1194/jlr.D017772

Tada, 2009, A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: application of the CD3/CD28 assay in lymphocytes, Clin Chim Acta, 400, 42, 10.1016/j.cca.2008.10.010

van der Westhuyzen, 1984, Low density lipoprotein receptor mutations in South African homozygous familial hypercholesterolemic patients, Arteriosclerosis, 4, 238, 10.1161/01.ATV.4.3.238

Mariotti, 2008, Rapid detection of mycoplasma in continuous cell lines using a selective biochemical test, Leuk Res, 32, 323, 10.1016/j.leukres.2007.04.010

Verhoeye, 1996, An improved method for detection of low density lipoprotein receptor defects in human T lymphocytes, J lipid Res, 37, 1377, 10.1016/S0022-2275(20)39168-9

Raungaard, 1998, Flow cytometry with a monoclonal antibody to the low density lipoprotein receptor compared with gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia, Clin Chem, 44, 966, 10.1093/clinchem/44.5.966

Ruotolo, 2014, The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family, Clin Chem Lab Med, 52, e175, 10.1515/cclm-2014-0144

Etxebarria, 2015, Functional characterization and classification of frequent low-density lipoprotein receptor variants, Hum Mutat, 36, 129, 10.1002/humu.22721

Ranheim, 2006, Model system for phenotypic characterization of sequence variations in the LDL receptor gene, Clin Chem, 52, 1469, 10.1373/clinchem.2006.068627

Wang, 2014, Functional characterization of two low-density lipoprotein receptor gene mutations in two Chinese patients with familial hypercholesterolemia, PloS one, 9, e92703, 10.1371/journal.pone.0092703

Wang, 2009, Mutations in the LDL receptor gene in four Chinese homozygous familial hypercholesterolemia phenotype patients, Nutr Metab Cardiovasc Dis, 19, 391, 10.1016/j.numecd.2008.07.011

Etxebarria, 2014, Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment, PloS one, 9, e112677, 10.1371/journal.pone.0112677

Khamis, 2015, Functional analysis of four LDLR 5'UTR and promoter variants in patients with familial hypercholesterolaemia, Eur J Hum Genet, 23, 790, 10.1038/ejhg.2014.199

Maurer, 2006, The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH, J cell Sci, 119, 4235, 10.1242/jcs.03217

Sorrentino, 2013, The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation, J lipid Res, 54, 2174, 10.1194/jlr.M037713

Pietiainen, 2013, NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation, J cell Sci, 126, 3961, 10.1242/jcs.128132

Alves, 2014, Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia, Hum Mol Genet, 23, 1817, 10.1093/hmg/ddt573

Raungaard, 2000, Flow cytometric assessment of LDL ligand function for detection of heterozygous familial defective apolipoprotein B-100, Clin Chem, 46, 224, 10.1093/clinchem/46.2.224

Frostegard, 1990, Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein, J lipid Res, 31, 37, 10.1016/S0022-2275(20)42758-0

Van den Broek, 1994, Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay, Clin Chem, 40, 395, 10.1093/clinchem/40.3.395

Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism, J lipid Res, S172, 10.1194/jlr.R800091-JLR200

Tibolla, 2011, Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition, Nutr Metab Cardiovasc Dis, 21, 835, 10.1016/j.numecd.2011.06.002

Flanagan, 2010, Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations, Genet Test Mol Biomark, 14, 533, 10.1089/gtmb.2010.0036

Abifadel, 2012, Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia, Atherosclerosis, 223, 394, 10.1016/j.atherosclerosis.2012.04.006

Fasano, 2009, Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells, Atherosclerosis, 203, 166, 10.1016/j.atherosclerosis.2008.10.027